EpiDestiny, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2016-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.epidestiny.com
To Study the Oral Bioavailability of a New Combination Formation of Decitabine and Tetrahydrouridine in Healthy Males
- First Posted Date
- 2023-04-18
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT05816356
- Locations
- 🇺🇸
Worldwide Clinical Trails Early Phase Services, San Antonio, Texas, United States
Effect of Food on the Pharmacokinetics of Decitabine/Tetrahydrouridine Combination Capsules in Healthy Adult Subjects
- First Posted Date
- 2019-09-11
- Last Posted Date
- 2020-01-22
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT04086238
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
A Study of Nicotinamide With Oral Tetrahydrouridine and Decitabine to Treat High Risk Sickle Cell Disease
- First Posted Date
- 2019-08-14
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04055818
- Locations
- 🇺🇸
University of Illinois at Chicago College of Medicine, Chicago, Illinois, United States
Randomized, Single-dose, Crossover Study of 4 Decitabine and Tetrahydrouridine (EPI01) Formulations in Healthy Subjects
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2019-05-09
- Lead Sponsor
- EpiDestiny, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03828084
- Locations
- 🇺🇸
Worldwide Clinical Trial, San Antonio, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath